Actualités Biogen (MM) - BGEN | Actions NASDAQ

MORNING UPDATE: Man Securities Issues Alerts for AMAT, BGEN, SCMR, VXGN, And CERN

MORNING UPDATE: Man Securities Issues Alerts for AMAT, BGEN, SCMR, VXGN, And CERN CHICAGO, Nov. 13 /PRNewswire/ -- Man Securities issues the...

Biogen und IDEC Pharmaceuticals schliessen Fusion zur Schaffung neuen führenden Biotechnologieunternehmens ab

Biogen und IDEC Pharmaceuticals schliessen Fusion zur Schaffung neuen f?hrenden Biotechnologieunternehmens ab CAMBRIDGE, Massachusetts, und SAN...

Biogen e IDEC Pharmaceuticals completan su fusión y crean un nuevo líder biotecnológico

Biogen e IDEC Pharmaceuticals completan su fusi?n y crean un nuevo l?der biotecnol?gico CAMBRIDGE, Massachusetts, November 13 /PRNewswire/ -- IDEC...

Biogen et IDEC Pharmaceuticals ont conclu une fusion qui donne naissance à un nouveau chef de file de l'industrie biotechnologi

Biogen et IDEC Pharmaceuticals ont conclu une fusion qui donne naissance ? un nouveau chef de file de l'industrie biotechnologique CAMBRIDGE...

Biogen and IDEC Pharmaceuticals Complete Merger to Create New Biotechnology Industry Leader

Biogen and IDEC Pharmaceuticals Complete Merger to Create New Biotechnology Industry Leader CAMBRIDGE, Massachusetts and SAN DIEGO, November 13...

Biogen and IDEC Pharmaceuticals Complete Merger to Create New Biotechnology Industry Leader

Biogen and IDEC Pharmaceuticals Complete Merger to Create New Biotechnology Industry Leader CAMBRIDGE, Mass., and SAN DIEGO, Nov. 12...

Biogen and IDEC Pharmaceuticals to Make Presentation at Credit Suisse First Boston Healthcare Conference

Biogen and IDEC Pharmaceuticals to Make Presentation at Credit Suisse First Boston Healthcare Conference CAMBRIDGE, Mass., and SAN DIEGO, Nov. 11...

Biogen anuncia los resultados de los ensayos de fase II con ADENTRI

Biogen anuncia los resultados de los ensayos de fase II con ADENTRI CAMBRIDGE, Massachusetts, November 10 /PRNewswire/ -- Biogen (Nasdaq: BGEN) ha...

Biogen Announces Results of Phase II Trials With ADENTRI at American Heart Association Meeting

Biogen Announces Results of Phase II Trials With ADENTRI at American Heart Association Meeting CAMBRIDGE, Mass., November 10 /PRNewswire/...

Biogen Announces Results of Phase II Trials With ADENTRI(TM) at American Heart Association Meeting

Biogen Announces Results of Phase II Trials With ADENTRI(TM) at American Heart Association Meeting CAMBRIDGE, Mass., Nov. 10...

SanDisk Corporation to Join the Nasdaq-100 Index Beginning November 13, 2003

SanDisk Corporation to Join the Nasdaq-100 Index Beginning November 13, 2003 NEW YORK, Nov. 6 /PRNewswire-FirstCall/ -- SanDisk Corporation of...

Standard & Poor's Announces Changes to S&P U.S. Indices

Standard & Poor's Announces Changes to S&P U.S. Indices NEW YORK, Nov. 6 /PRNewswire/ -- Standard & Poor's will make the following changes in...

Total Revenues Up 19 Percent Year-Over-Year

Total Revenues Up 19 Percent Year-Over-Year Biogen's Third Quarter 2003 Reported EPS of $0.36 Increased 30 Percent Year- Over-Year; Operating EPS...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Biogen (MM) (BGEN)

Outils de qualité professionnelle, pour des investisseurs individuels.

BGEN Actualités

MORNING UPDATE: Man Securities Issues Alerts for AMAT, BGEN, SCMR, VXGN, And CERN

Biogen und IDEC Pharmaceuticals schliessen Fusion zur Schaffung neuen führenden Biotechnologieunternehmens ab

Biogen e IDEC Pharmaceuticals completan su fusión y crean un nuevo líder biotecnológico

Biogen et IDEC Pharmaceuticals ont conclu une fusion qui donne naissance à un nouveau chef de file de l'industrie biotechnologi

Biogen and IDEC Pharmaceuticals Complete Merger to Create New Biotechnology Industry Leader

Biogen and IDEC Pharmaceuticals Complete Merger to Create New Biotechnology Industry Leader

Biogen and IDEC Pharmaceuticals to Make Presentation at Credit Suisse First Boston Healthcare Conference

Biogen anuncia los resultados de los ensayos de fase II con ADENTRI

Biogen Announces Results of Phase II Trials With ADENTRI at American Heart Association Meeting

Biogen Announces Results of Phase II Trials With ADENTRI(TM) at American Heart Association Meeting

SanDisk Corporation to Join the Nasdaq-100 Index Beginning November 13, 2003

Standard & Poor's Announces Changes to S&P U.S. Indices

Total Revenues Up 19 Percent Year-Over-Year

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Biogen (MM) (BGEN) Actualités

Biogen (MM) (BGEN)

Outils de qualité professionnelle, pour des investisseurs individuels.

BGEN Actualités

MORNING UPDATE: Man Securities Issues Alerts for AMAT, BGEN, SCMR, VXGN, And CERN

Biogen und IDEC Pharmaceuticals schliessen Fusion zur Schaffung neuen führenden Biotechnologieunternehmens ab

Biogen e IDEC Pharmaceuticals completan su fusión y crean un nuevo líder biotecnológico

Biogen et IDEC Pharmaceuticals ont conclu une fusion qui donne naissance à un nouveau chef de file de l'industrie biotechnologi

Biogen and IDEC Pharmaceuticals Complete Merger to Create New Biotechnology Industry Leader

Biogen and IDEC Pharmaceuticals Complete Merger to Create New Biotechnology Industry Leader

Biogen and IDEC Pharmaceuticals to Make Presentation at Credit Suisse First Boston Healthcare Conference

Biogen anuncia los resultados de los ensayos de fase II con ADENTRI

Biogen Announces Results of Phase II Trials With ADENTRI at American Heart Association Meeting

Biogen Announces Results of Phase II Trials With ADENTRI(TM) at American Heart Association Meeting

SanDisk Corporation to Join the Nasdaq-100 Index Beginning November 13, 2003

Standard & Poor's Announces Changes to S&P U.S. Indices

Total Revenues Up 19 Percent Year-Over-Year

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités